Cardiac allograft vasculopathy (CAV) is a pathologic immune-mediated remodelling of the
vasculature in transplanted hearts and, by impairing perfusion, is the major cause of late …

Orthotropic heart transplantation remains the most effective therapy for patients with end-
stage heart failure, with a median survival of≈ 13 years. Yet, a number of complications are …

Background: Transplant arteriosclerosis is a major complication in long-term survivors of
heart transplantation. Increased lymph flow from donor heart to host lymph nodes has been …

Cardiovascular disease is the most important cause of death worldwide in recent years; an
increasing trend is also shown in organ transplant patients subjected to immunosuppressive …

Novel risk stratification and non‐invasive surveillance methods are needed in orthotopic
heart transplant (OHT) to reduce morbidity and mortality post‐transplant. Clonal …

Cardiac allograft vasculopathy (CAV) limits the long-term success of heart transplants.
Generation of donor-specific antibodies (DSAs) is associated with increased incidence of …

Background. Glucagon-like peptide 1 receptor agonists (GLP1-RAs) reduce cardiovascular
events and mortality in type 2 diabetes. Limited data are available on diabetes treatment …

Background Cardiac allograft vasculopathy (CAV) is characterized by diffuse thickening of
the arterial intima. Statins reduce the incidence of CAV, but despite the use of statins, CAV …

Introduction Cardiac allograft vasculopathy (CAV) limits long‐term survival in heart
transplant (HTx) recipients. The use of biomarkers in CAV surveillance has been studied, but …

Despite advances in the care of heart transplant recipients during the past 5 decades,
cardiac allograft vasculopathy (CAV) continues to be a major barrier to long-term survival …